← Back to Search

Corticosteroid

Needle-free Triamcinolone for Alopecia Areata

Phase 4
Waitlist Available
Led By Sonal Shah, MD
Research Sponsored by University Hospitals Cleveland Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient has at least 2 alopecic patches each measuring at least 2 cm2 and are…
Located on contralateral body sites OR Within the same body site but separated by ≥ 1 cm
Must not have
Patient has alopecia totalis, alopecia universalis, or alopecia areata with ophiasis pattern
Patient is unable/unwilling to provide informed assent when applicable
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group
Pivotal Trial
Drug Has Already Been Approved

Summary

This trial is testing a needle-free device called Med-Jet to give medicine to children with patchy hair loss. The device uses pressure instead of needles, which might be less painful and more effective.

Who is the study for?
This trial is for children with patchy hair loss (alopecia areata) who have at least two bald patches and can receive a treatment without needles. They must be diagnosed by a specialist or through a skin biopsy, and not have total hair loss or certain patterns of alopecia. Kids taking meds that affect pain sensation, those allergic to the medication used, pregnant teens, or those with an infection where the drug will go can't join.
What is being tested?
The study tests if using the MedJet device to deliver triamcinolone (a steroid) without needles is bearable for kids with alopecia areata. It checks if this method works well and safely improves their quality of life over four to five visits.
What are the potential side effects?
Possible side effects include discomfort from the needle-free device and reactions to triamcinolone like skin thinning at the treated area, changes in color on site of injection, headache, stuffy nose, sore throat or coughing.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have at least two bald patches, each measuring at least 2 square centimeters.
Select...
The things being studied are either on opposite sides of the body or are at least 1 centimeter apart on the same side.
Select...
You have at least 2 bald patches on different sides of your body, or on the same side but at least 1 cm apart.
Select...
You have at least 2 bald patches, each at least the size of a quarter, on different parts of your body or at least 1 inch apart on the same body part.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
You have total hair loss, universal hair loss, or a specific pattern of hair loss called ophiasis.
Select...
You have a medical condition or take a medication that affects how you feel pain when getting an injection.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Determine Patient Tolerability of Needle-free Delivery of Intralesional Triamcinolone Using the Patient-reported Outcomes of a Pain Score Assessment and a Patient Survey.
Secondary study objectives
Change in Alopecia Areata- Investigator Global Assessment (AA-IGA)
Change in Patient Reported Hair Loss
Change in Severity of Alopecia Tool (SALT) Score
+4 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.

Trial Design

1Treatment groups
Experimental Treatment
Group I: MedJet DeviceExperimental Treatment1 Intervention
The Med-Jet-MBX needle-free injector (Med-Jet) is a novel, needle-free drug-delivery system, which we believe may be a solution to the pain and fear associated with needles. It uses regulated compressed air as a power source to accelerate an injectable fluid through a 0.005" orifice (6x smaller than a 30G needle) to penetrate the skin and deliver medication to a specific anatomical region (MedJet) The drug-delivery device is highly configurable allowing adjustable depth and volume parameters (MedJet). In addition, the high-performance design allows for triggering multiple injection sites rapidly which is practical when needing to treat large surface areas (MedJet).

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Alopecia Areata include intralesional corticosteroids like triamcinolone acetonide, which work by reducing inflammation and modulating the immune response that attacks hair follicles. Topical immunotherapies such as diphenylcyclopropenone (DPCP) and squaric acid dibutyl ester (SADBE) induce a mild allergic reaction to divert the immune system from attacking hair follicles. Systemic immunosuppressants like methotrexate and cyclosporine suppress the overall immune response to prevent hair loss. These mechanisms are crucial for patients as they target the underlying autoimmune process, offering potential for hair regrowth and improving quality of life.
Multi-Concentration Level Patch Test Guided Diphenyl Cyclopropenone (DPCP) Treatment in Alopecia Totalis or Alopecia Universalis.Interventions for alopecia areata.

Find a Location

Who is running the clinical trial?

University Hospitals Cleveland Medical CenterLead Sponsor
320 Previous Clinical Trials
339,986 Total Patients Enrolled
1 Trials studying Alopecia Areata
14 Patients Enrolled for Alopecia Areata
Sonal Shah, MDPrincipal InvestigatorUniversity Hospitals Cleveland Medical Center

Media Library

Intralesional Triamcinolone (Corticosteroid) Clinical Trial Eligibility Overview. Trial Name: NCT05278858 — Phase 4
Alopecia Areata Research Study Groups: MedJet Device
Alopecia Areata Clinical Trial 2023: Intralesional Triamcinolone Highlights & Side Effects. Trial Name: NCT05278858 — Phase 4
Intralesional Triamcinolone (Corticosteroid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05278858 — Phase 4
Alopecia Areata Patient Testimony for trial: Trial Name: NCT05278858 — Phase 4
~1 spots leftby Oct 2025